Pay in 4 interest-free payments of $6.10 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
For advanced HCC patients receiving tyrosine kinase inhibitor therapy, transjugular intrahepatic portosystemic shunt combined with -AR antagonists could reduce the rebleeding rate (5.8% vs
Y.Ozkan-DagliyanI.GaddameedhiS.SancarA
Semaglutide, developed by Novo Nordisk and approved by the EMA in 2018, marked a substantial leap forward with its once-weekly dosing schedule
doi: 10.1111/imm.13924 243 SongRLiTYeJSunFHouBSaeedMet al
Author disclaimer This publication is solely the responsibility of the authors and does not necessarily represent the official view of NIH nor any other funder
GLP-1-based treatments mark a major advancement in managing obesity and type 2 diabetes, offering added benefits for heart and brain health
US$ 20.01
US$ 29.19
US$ 25.78
US$ 27.24
US$ 20.44
US$ 20.66
US$ 27.46
